These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 29694732)

  • 1. Pharmacokinetic Interaction Between Fingolimod and Carbamazepine in Healthy Subjects.
    David OJ; Behrje R; Pal P; Hara H; Lates CD; Schmouder R
    Clin Pharmacol Drug Dev; 2018 Aug; 7(6):575-586. PubMed ID: 29694732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of CYP3A4 induction/inhibition on the pharmacokinetics of vilazodone in healthy subjects.
    Boinpally R; Gad N; Gupta S; Periclou A
    Clin Ther; 2014 Nov; 36(11):1638-49. PubMed ID: 25236915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of ceralifimod (ONO-4641) on lymphocytes and cardiac function: Randomized, double-blind, placebo-controlled trial with an open-label fingolimod arm.
    Krösser S; Wolna P; Fischer TZ; Boschert U; Stoltz R; Zhou M; Darpo B
    J Clin Pharmacol; 2015 Sep; 55(9):1051-60. PubMed ID: 25855155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of fingolimod and metabolites in subjects with severe renal impairment: An open-label, single-dose, parallel-group study.
    David OJ; Pryce M; Meiser K; Picard F; Emotte C; Kobalava Z; Moiseev V; Schmouder R
    Int J Clin Pharmacol Ther; 2015 Oct; 53(10):847-54. PubMed ID: 26308173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Cytochrome P450 (CYP) 3A4-Based Interactions of Levomilnacipran with Ketoconazole, Carbamazepine or Alprazolam in Healthy Subjects.
    Chen L; Boinpally R; Gad N; Greenberg WM; Wangsa J; Periclou A; Ghahramani P
    Clin Drug Investig; 2015 Oct; 35(10):601-12. PubMed ID: 26315684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioequivalence of oral and intravenous carbamazepine formulations in adult patients with epilepsy.
    Tolbert D; Cloyd J; Biton V; Bekersky I; Walzer M; Wesche D; Drummond R; Lee D
    Epilepsia; 2015 Jun; 56(6):915-23. PubMed ID: 25982590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioequivalence Study of 2 Capsule Formulations of Fingolimod 0.5 mg Assessing Both Parent Drug and Active Metabolite in New Zealand Healthy Subjects (Truncated Design).
    Hung NA; Costa FG; Hung CT; Rosenberg ME
    Clin Pharmacol Drug Dev; 2020 Jul; 9(5):610-620. PubMed ID: 32468719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the Pharmacokinetic Interaction Between the Voltage- and Use-Dependent Nav1.7 Channel Blocker Vixotrigine and Carbamazepine in Healthy Volunteers.
    Dunbar J; Versavel M; Zhao Y; Tate S; Morisset V; Giblin GMP; Palmer J; Tidemann-Miller B; Naik H
    Clin Pharmacol Drug Dev; 2020 Jan; 9(1):62-73. PubMed ID: 31650711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Piperine on the Metabolism and Pharmacokinetics of Carbamazepine in Healthy Volunteers.
    Bedada SK; Appani R; Boga PK
    Drug Res (Stuttg); 2017 Jan; 67(1):46-51. PubMed ID: 27776366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation.
    Song I; Weller S; Patel J; Borland J; Wynne B; Choukour M; Jerva F; Piscitelli S
    Eur J Clin Pharmacol; 2016 Jun; 72(6):665-70. PubMed ID: 26898568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9/3A4 inducer, in healthy subjects.
    Gardin A; Gray C; Neelakantham S; Huth F; Davidson AM; Dumitras S; Legangneux E; Shakeri-Nejad K
    Eur J Clin Pharmacol; 2018 Dec; 74(12):1593-1604. PubMed ID: 30105453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers.
    Darwish M; Yang R; Tracewell W; Robertson P; Bond M
    Clin Ther; 2015 Feb; 37(2):390-401. PubMed ID: 25542074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers.
    Miceli JJ; Anziano RJ; Robarge L; Hansen RA; Laurent A
    Br J Clin Pharmacol; 2000; 49 Suppl 1(Suppl 1):65S-70S. PubMed ID: 10771457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brivaracetam and carbamazepine interaction in healthy subjects and in vitro.
    Stockis A; Chanteux H; Rosa M; Rolan P
    Epilepsy Res; 2015 Jul; 113():19-27. PubMed ID: 25986188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of carbamazepine on the pharmacokinetics of paliperidone extended-release tablets at steady-state.
    Kerbusch-Herben V; Cleton A; Berwaerts J; Vandebosch A; Remmerie B
    Clin Pharmacol Drug Dev; 2014 Sep; 3(5):371-7. PubMed ID: 27129010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect on heart rate of combining single-dose fingolimod with steady-state atenolol or diltiazem in healthy subjects.
    Kovarik JM; Lu M; Riviere GJ; Barbet I; Maton S; Goldwater DR; Schmouder RL
    Eur J Clin Pharmacol; 2008 May; 64(5):457-63. PubMed ID: 18196225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the potential for pharmacokinetic drug-drug interaction between armodafinil and carbamazepine in healthy adults.
    Darwish M; Bond M; Yang R; Hellriegel ET; Robertson P
    Clin Ther; 2015 Feb; 37(2):325-37. PubMed ID: 25438721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carbamazepine-nefazodone interaction in healthy subjects.
    Laroudie C; Salazar DE; Cosson JP; Cheuvart B; Istin B; Girault J; Ingrand I; Decourt JP
    J Clin Psychopharmacol; 2000 Feb; 20(1):46-53. PubMed ID: 10653208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of resveratrol on the pharmacokinetics of carbamazepine in healthy human volunteers.
    Bedada SK; Nearati P
    Phytother Res; 2015 May; 29(5):701-6. PubMed ID: 25624269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ketoconazole increases fingolimod blood levels in a drug interaction via CYP4F2 inhibition.
    Kovarik JM; Dole K; Riviere GJ; Pommier F; Maton S; Jin Y; Lasseter KC; Schmouder RL
    J Clin Pharmacol; 2009 Feb; 49(2):212-8. PubMed ID: 19118083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.